دورية أكاديمية
أعرض في EDS

Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines.

التفاصيل البيبلوغرافية
العنوان: Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines.
المؤلفون: Hausdorff WP; Center for Vaccine Innovation and Access, PATH, 455 Massachusetts Ave NW, Washington, DC 20001, USA.; Faculty of Medicine, Université Libre de Bruxelles, 1070 Brussels, Belgium., Price J; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA 98121, USA., Debellut F; Center for Vaccine Innovation and Access, PATH, Rue de Varembé 7, 1202 Geneva, Switzerland., Mooney J; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA 98121, USA., Torkelson AA; Linksbridge SPC, 808 5th Ave N, Seattle, WA 98109, USA., Giorgadze K; Linksbridge SPC, 808 5th Ave N, Seattle, WA 98109, USA., Pecenka C; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA 98121, USA.
المصدر: Vaccines [Vaccines (Basel)] 2022 Jan 20; Vol. 10 (2). Date of Electronic Publication: 2022 Jan 20.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG
مستخلص: Routine infant immunization with live, oral rotavirus vaccines (LORVs) has had a major impact on severe gastroenteritis disease. Nevertheless, in high morbidity and mortality settings rotavirus remains an important cause of disease, partly attributable to the sub-optimal clinical efficacy of LORVs in those settings. Regardless of the precise immunological mechanism(s) underlying the diminished efficacy, the introduction of injectable next-generation rotavirus vaccines (iNGRV), currently in clinical development, could offer a potent remedy. In addition to the potential for greater clinical efficacy, precisely how iNGRVs are delivered (multiple doses to young infants; alongside LORVs or as a booster; co-formulated with Diphtheria-Tetanus-Pertussis (DTP)-containing vaccines), their pricing, and their storage and cold chain characteristics could each have major implications on the resultant health outcomes, on cost-effectiveness as well as on product preferences by national stakeholders and healthcare providers. To better understand these implications, we critically assessed whether there is a compelling public health value proposition for iNGRVs based on potential (but still hypothetical) vaccine profiles. Our results suggest that the answer is highly dependent on the specific use cases and potential attributes of such novel vaccines. Notably, co-formulation of iNGRVs with similar or greater efficacy than LORVs with a DTP-containing vaccine, such as DTP-Hib-HepB, scored especially high on potential impact, cost-effectiveness, and strength of preference by national stakeholders and health care providers in lower and middle income countries.
References: J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S331-S342. (PMID: 34590142)
N Engl J Med. 2018 Feb 22;378(8):719-730. (PMID: 29466164)
Sci Transl Med. 2019 Aug 14;11(505):. (PMID: 31413144)
Vaccine. 2016 Jan 20;34(4):413-423. (PMID: 26691569)
PLoS One. 2017 Sep 11;12(9):e0183392. (PMID: 28892480)
Expert Opin Biol Ther. 2022 Mar;22(3):423-432. (PMID: 34482790)
PLoS One. 2020 Jun 10;15(6):e0233950. (PMID: 32520934)
Vaccine. 2017 Nov 1;35(46):6255-6263. (PMID: 28986035)
Lancet Infect Dis. 2020 Jul;20(7):851-863. (PMID: 32251641)
J Infect Dis. 2018 Mar 5;217(6):861-868. (PMID: 29514306)
Vaccine. 2022 Jan 21;40(2):370-379. (PMID: 34863614)
Value Health. 2019 Aug;22(8):942-952. (PMID: 31426936)
Clin Infect Dis. 2017 Sep 1;65(5):840-850. (PMID: 28444323)
PLoS Med. 2021 Aug 10;18(8):e1003721. (PMID: 34375328)
Vaccine. 2020 Dec 14;38(52):8247-8254. (PMID: 33234304)
Lancet Infect Dis. 2018 Nov;18(11):1211-1228. (PMID: 30243583)
Nature. 2018 Dec;564(7736):337-339. (PMID: 30560957)
Vaccine. 2019 May 21;37(23):3040-3049. (PMID: 31027927)
Vaccine. 2021 Apr 1;39(14):1897-1909. (PMID: 33750592)
Lancet. 2013 Jul 20;382(9888):209-22. (PMID: 23680352)
Vaccine. 2017 Dec 18;35(51):7198-7203. (PMID: 29169893)
J Infect Dis. 2018 Mar 5;217(6):851-853. (PMID: 29394364)
Lancet Infect Dis. 2019 Jul;19(7):717-727. (PMID: 31178289)
Hum Vaccin Immunother. 2019;15(6):1215-1227. (PMID: 30735087)
Hum Vaccin Immunother. 2021 Jun 3;17(6):1787-1802. (PMID: 33327868)
معلومات مُعتمدة: OPP 1203883 United States GATES Bill & Melinda Gates Foundation
فهرسة مساهمة: Keywords: combination vaccines; cost-effectiveness; gastroenteritis; product preferences; rotavirus; value proposition
تواريخ الأحداث: Date Created: 20220226 Latest Revision: 20220301
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8880741
DOI: 10.3390/vaccines10020149
PMID: 35214608
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-393X
DOI:10.3390/vaccines10020149